64539 vivorte 079
Vivorte v9 blk

Vivorté

Performance Biologics for orthopedic surgery

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Louisville, KY, USA
  • Currency USD
  • Founded December 2010
  • Employees 8
  • Incorporation Type C-corp
  • Website vivorte.com

Company Summary

Vivorté’s mission is to invent, develop and commercialize innovative biomaterials for orthopedic surgery. The company operates within a vast $1.7B (U.S.) market for orthobiologics, however is focused on developing specialty products to address unmet clinical needs in orthopedic trauma, joint replacement, oncology and foot/ankle surgery. Vivorté has reached commercial stage and seeks continued capital to continue its growth trajectory.

Team

  • Fbec5a77 a2c4 4cad a8dc 0961f90b5027
    Co-Founder

    Ruth worked for more than 18 years at Johnson & Johnson. Ms. Voor was the Executive Director of Drug Eluting Stent Commercialization for J&J, leading the team that took CYPHER® Drug Eluting Stent from concept to launch and global approval in less than 4 years, achieving $1B in US sales in the first 9 months. She received a BS from the United States Naval Academy.

  • 364e8614 0065 4e5b 80a4 f30258debf22
    CSO and Co-Founder

    Dr. Voor is the Director of the Orthopaedic Bioengineering Laboratory at the University of Louisville. He has over 60 peer-reviewed publications, has secured over $3M in research funding and consulted on projects with many large orthopedic companies. Dr. Voor has authored several patents and has a bone fixation device, which is sold by DePuy Spine, Inc. He received his PhD from Tulane University’s Department of Biomedical Engineering.

  • Mark has extensive experience leading commercial organizations within the medical device industry. Previously, he was Senior Director of Sales and Marketing at DCI Donor Services, leading the commercialization within the orthopedics, spine and wound care market segments. Mr. Wagner also held leadership positions at AmerisourceBergen, Angiotech Pharmaceuticals and RTI Surgical. He received his MBA from Northwestern (Kellogg).

Advisors